NO20084317L - Metoder for a behandle lupus ved bruk av CD4 antistoff - Google Patents

Metoder for a behandle lupus ved bruk av CD4 antistoff

Info

Publication number
NO20084317L
NO20084317L NO20084317A NO20084317A NO20084317L NO 20084317 L NO20084317 L NO 20084317L NO 20084317 A NO20084317 A NO 20084317A NO 20084317 A NO20084317 A NO 20084317A NO 20084317 L NO20084317 L NO 20084317L
Authority
NO
Norway
Prior art keywords
methods
antibody
lupus
depleting
administration
Prior art date
Application number
NO20084317A
Other languages
English (en)
Inventor
Bryan Irving
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20084317L publication Critical patent/NO20084317L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sammendrag Fremgangsmåter for behandling av lupus som inkluderer systemisk lupus erytematose, kutant lupus erytemetose og lupus nefritt, er tilveiebrakt. Fremgangsmåtene involverer administrasjon av en kombinasjon av et ikke-deplerende CD4-antistoff og en annen forbindelse anvendt klinisk eller eksperimentelt for behandling av lupus. Fremgangsmåter for behandling av lupus nefritt ved administrasjon av et ikke-deplerende CD4antistoff som resulterer i en forbedring i renal funksjon og/eller en reduksjon i proteinuri eller aktiv urinsediment er også tilveiebrakt. Fremgangsmåter for behandling av multippel sklerose ved administrasjon av et ikke-deplerende CD4-antistoff, eventuelt i kombinasjon med en andre forbindelse anvendt klinisk eller eksperimentelt for å behandle MS, er beskrevet. Fremgangsmåter for behandling av transplantatresipienter og subjekter med reumatoid artritt, astma, psoriasis, Crohns sykdom, ulcerativ kolitt og Sjogrens syndrom, er også tilveiebrakt.
NO20084317A 2006-03-16 2008-10-15 Metoder for a behandle lupus ved bruk av CD4 antistoff NO20084317L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78353506P 2006-03-16 2006-03-16
US87388106P 2006-12-07 2006-12-07
PCT/US2007/006443 WO2007109052A2 (en) 2006-03-16 2007-03-14 Methods of treating lupus using cd4 antibodies

Publications (1)

Publication Number Publication Date
NO20084317L true NO20084317L (no) 2008-12-09

Family

ID=38522934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084317A NO20084317L (no) 2006-03-16 2008-10-15 Metoder for a behandle lupus ved bruk av CD4 antistoff

Country Status (12)

Country Link
US (1) US20070218062A1 (no)
EP (1) EP2001510A4 (no)
JP (1) JP2009530290A (no)
KR (1) KR20080112300A (no)
AU (1) AU2007227609A1 (no)
BR (1) BRPI0708902A2 (no)
CA (1) CA2645322A1 (no)
IL (1) IL193920A0 (no)
MX (1) MX2008011785A (no)
NO (1) NO20084317L (no)
RU (1) RU2008137765A (no)
WO (1) WO2007109052A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2695999T3 (es) * 2007-10-12 2019-01-11 Hoffmann La Roche Expresión de proteínas a partir de múltiples ácidos nucleicos
JP5795167B2 (ja) 2008-03-13 2015-10-14 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
BRPI0909048A2 (pt) * 2008-03-13 2015-11-24 Biotest Ag composição farmacêutica, e, método de tratamento de uma doença autoimune
JP5604311B2 (ja) * 2008-03-13 2014-10-08 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
WO2010009129A2 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Methods of treating autoimmune diseases using cd4 antibodies
WO2010036706A1 (en) * 2008-09-23 2010-04-01 The Trustees Of The University Of Pennsylvania Recombination sequence (rs) rearrangement frequency as a measure of central b cell tolerance
AU2009296078B2 (en) * 2008-09-29 2015-08-20 Biotest Ag Composition for treating disease
PT2344540T (pt) 2008-10-02 2018-02-02 Aptevo Res & Development Llc Proteínas de ligação multi-alvo antagonistas de cd86
KR20190025057A (ko) * 2008-10-14 2019-03-08 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
EP2486152B1 (en) 2009-10-07 2017-12-06 F. Hoffmann-La Roche AG Methods for diagnosing lupus
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
SG10201501535UA (en) * 2010-03-03 2015-04-29 Teva Pharma Treatment of lupus nephritis using laquinimod
DE102011082871A1 (de) * 2011-09-16 2013-03-21 Florian, Prof. Dr. Lang Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen
AU2013214909A1 (en) 2012-02-03 2014-09-18 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
JP6861456B2 (ja) * 2015-04-28 2021-04-21 オルフィディア リミテッド アナライトの検出およびそのための方法
EP3782645A4 (en) * 2018-04-17 2022-01-12 National Cancer Center CANCER T LYMPHOCYTE THERAPY PRODUCT ASSISTING COMPOSITION COMPRISING AN ANTI-CD4 MONOCLONAL ANTIBODY INDUCING CD4+ LYMPHOCYTE DEPLETION AND USE THEREOF
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US77275A (en) * 1868-04-28 Improvement in tee manufacture of packing foe steam-engines
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4690905A (en) * 1983-11-16 1987-09-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method for removal of human antibodies to native DNA from serum
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
GB9100741D0 (en) * 1991-01-14 1991-02-27 Univ London Treatment of disease
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
MX9305070A (es) * 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
AU5605398A (en) * 1996-12-11 1998-07-03 University Of Florida Novel methods and compositions for treatment of autoimmune diseases
GB2376466A (en) * 2001-06-14 2002-12-18 Mark Frewin TRX1 antibody
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
MXPA06014069A (es) * 2004-06-04 2007-04-25 Genentech Inc Metodo para tratar esclerosis multiple.
AU2005251764A1 (en) * 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
BRPI0512017A (pt) * 2004-06-22 2008-02-06 Tolerrx Inc dosagem otimizada com anticorpos anti-cd4 para indução de toleráncia em primatas

Also Published As

Publication number Publication date
EP2001510A2 (en) 2008-12-17
BRPI0708902A2 (pt) 2011-06-14
KR20080112300A (ko) 2008-12-24
AU2007227609A1 (en) 2007-09-27
US20070218062A1 (en) 2007-09-20
MX2008011785A (es) 2008-09-25
WO2007109052A2 (en) 2007-09-27
CA2645322A1 (en) 2007-09-27
RU2008137765A (ru) 2010-04-27
IL193920A0 (en) 2011-08-01
JP2009530290A (ja) 2009-08-27
EP2001510A4 (en) 2010-06-09
WO2007109052A3 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
NO20084317L (no) Metoder for a behandle lupus ved bruk av CD4 antistoff
Martel et al. Purported nanobacteria in human blood as calcium carbonate nanoparticles
NO20080125L (no) 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament
NO20090093L (no) Profylaktisk eller terapeutisk middel for inflammatorisk sykdom
BR112012012912A2 (pt) anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra.
NO20072733L (no) Doseformer
WO2010056898A3 (en) Rapid expression cloning of human monoclonal antibodies from memory b cells
WO2006052555A8 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
Mo et al. Basiliximab for steroid‐refractory acute graft‐versus‐host disease: a real‐world analysis
NO20055884L (no) Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt
WO2007127480A3 (en) Materials and methods to reduce low density lipoprotein cholesterol
Singh et al. Nasal microbiota imbalance as a contributory link in the emergence of COVID-19 associated mucormycosis
WO2011084791A3 (en) Early marker of proteinuria in patients treated with an anti-vegf treatment
WO2006044665A3 (en) Neuroprotective spirostenol pharmaceutical compositions
Zoccali Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?
Wu Mechanism and countermeasures for action of scientific and technological innovation on integration of industrialization and urbanization
Zhong-Lei et al. Clinical analysis of 91 cases of imported falciparum malaria from Africa
Park et al. Outcome of cadaveric kidney transplantation from expanded criteria donors
朱诚意 et al. The evolution of inclusions in high quality GCr15 bearing steels during secondary refining process
WO2007067478A3 (en) P38 kinase inhibiting agents
Faure et al. Association non fortuite de lymphome thyroïdien et de thyroïdite d’Hashimoto. Surveillance per-thérapeutique difficile
Church et al. Inhibition Of P38 Mitogen Activated Protein Kinase (MAPK) Prevents And Reverses Experimental Pulmonary Hypertension
Brock The LLR TAP IcICLLe trial assessing biological response to ibrutinib in CLL: Immediate disease redistribution precedes cell cycle arrest by 2 weeks with reduced bone marrow infiltration by 6 months
Carlsen Hepatitis: case report

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application